Biophytis SA

Paris, I0 · CIK 0001768946 · Biotech · Private

Small-molecule therapeutic compounds targeting aging and age-related diseases, with lead candidate BIO 101

biophytis.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$4.2M
2 Form D · Sep 2026
1 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$1,584,275
Private capital raisedForm D · SEC$2,598,526
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1537F2G——
1538Glyco Expression Technologies (Corporation)——
1539Purilogics, LLC——
1540Biophytis SA—$4.2M
1541Potrero Hill Therapeutics——
15423HELIX INC—$12M
1543Adcytherix——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 9 related persons
  • Claude AllaryDirector
  • Chiara BaccelliExecutive Officer
  • Edouard BiethExecutive Officer
  • Nadine CoulmDirector
  • Christophe CourtillatExecutive Officer
  • Pierre DildaExecutive Officer
  • Waly DiohExecutive Officer
  • Jean MarianiDirector · Executive Officer
  • Stanislas VeilletDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.